Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
WALTHAM, Mass., July 18, 2017 -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that the Compensation Committee of the Company’s Board of Directors granted Jesper Høiland, the Company’s President and Chief Executive Officer, an option to purchase 305,000 shares of the Company’s common stock with a per share exercise price of $42.97, the closing trading price of the Company’s common stock on the NASDAQ Global Market on the grant date of July 17, 2017. The option vests 25% on the first anniversary of the grant date, with the remaining 75% to vest in monthly installments over the three years thereafter, and has a ten-year term. The stock option was granted pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules for equity grants to induce Mr. Høiland to enter into employment with the Company.
About Radius
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius’ lead product, TYMLOS™ (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius’ Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius’ RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. For more information, please visit www.radiuspharm.com.
Investor Relations Contact: Barbara Ryan Email: [email protected] Phone: 203-274-2825
